Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

NORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host a conference call webcast on Monday, September 14 at 8:00 a.m. EDT, to discuss topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of obesity. Harold Bays, M.D., an investigator for the study, will be a guest speaker in the event. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management and a new therapeutic option for obesity beyond GLP-1 and other incretin-targeting therapies.